Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials

BACKGROUND: The clinical benefit of aspirin for the primary prevention of cardiovascular disease (CVD) in diabetes remains uncertain. To evaluate the efficacy and safety of aspirin for the primary prevention of cardiovascular outcomes and all-cause mortality events in people with diabetes, we conduc...

Descripción completa

Detalles Bibliográficos
Autores principales: Seidu, Samuel, Kunutsor, Setor K., Sesso, Howard D., Gaziano, J. M., Buring, J. E., Roncaglioni, Maria Carla, Khunti, Kamlesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547459/
https://www.ncbi.nlm.nih.gov/pubmed/31159806
http://dx.doi.org/10.1186/s12933-019-0875-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547459/
https://www.ncbi.nlm.nih.gov/pubmed/31159806
http://dx.doi.org/10.1186/s12933-019-0875-4

Ejemplares similares